A phase 2 trial of dasatinib in advanced melanoma

Cancer

Volumn 117, Issue 10, 2011, Pages 2202-2208

  Kluger, Harriet M ^a   Dudek, Arkadiuz Z ^b   McCann, Carrie ^b   Ritacco, Jean ^a   Southard, Nadine ^a   Jilaveanu, Lucia B ^a   Molinaro, Annette ^c   Sznol, Mario ^a  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

dasatinib; melanoma; src kinases

Indexed keywords

DASATINIB;

ADULT; ANOREXIA; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEARTBURN; HUMAN; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOGENE C KIT; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; TASTE DISORDER; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; THIAZOLES;

EID: 79955500900     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25766     Document Type: Article

References (34)

1. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26: 5233-5239.
2. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009; 15: 5591-5598.
3. Jilaveanu LB, Aziz SA, Kluger HM,. Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol. 2009; 27: 614-625.
4. Flaherty KT, Hodi FS, Bastian BC,. Mutation-driven drug development in melanoma. Curr Opin Oncol. 2010; 22: 178-183.
5. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008; 26: 2046-2051.
6. Garrido MC, Bastian BC,. KIT as a therapeutic target in melanoma. J Invest Dermatol. 2010; 130: 20-27.
7. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47: 6658-6661. (Pubitemid 40053752)
8. Das J, Chen P, Norris D, et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006; 49: 6819-6832. (Pubitemid 44749749)
9. Pavlu J, Marin D,. Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials. Clin Lymphoma Myeloma. 2009; 9: 417-424.
10. von Mehren M,. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer. 2006;(6 suppl 1): S30-S34.
11. Araujo J, Logothetis C,. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev. 2010; 36: 492-500.
12. Demetri GD, Lo Russo P, MacPherson IR, et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009; 15: 6232-6240.
13. Halaban R, Kwon BS, Ghosh S, Delli Bovi P, Baird A,. bFGF as an autocrine growth factor for human melanomas. Oncogene Res. 1988; 3: 177-186. (Pubitemid 19085035)
14. Yayon A, Ma YS, Safran M, Klagsbrun M, Halaban R,. Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases. Oncogene. 1997; 14: 2999-3009. (Pubitemid 27336315)
15. Yeatman TJ,. A renaissance for SRC. Nat Rev Cancer. 2004; 4: 470-480. (Pubitemid 38745532)
16. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002; 21: 7001-7010. (Pubitemid 35252974)
17. Mirmohammadsadegh A, Hassan M, Bardenheuer W, et al. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases. J Invest Dermatol. 2006; 126: 2272-2280. (Pubitemid 44413174)
18. O'Connor TJ, Neufeld E, Bechberger J, Fujita DJ,. pp60c-src in human melanocytes and melanoma cells exhibits elevated specific activity and reduced tyrosine 530 phosphorylation compared to human fibroblast pp60c-src. Cell Growth Differ. 1992; 3: 435-442.
19. Furuhashi M, Sjoblom T, Abramsson A, et al. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res. 2004; 64: 2725-2733. (Pubitemid 38500608)
20. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J,. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene. 2005; 24: 7859-7868. (Pubitemid 41715192)
21. Sohaib SA, Turner B, Hanson JA, Farquharson M, Oliver RT, Reznek RH,. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol. 2000; 73: 1178-1184.
22. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006; 24: 4764-4774. (Pubitemid 46630941)
23. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006; 24: 4738-4745. (Pubitemid 46630937)
24. Simon R,. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10. (Pubitemid 19099520)
25. Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009; 8: 2079-2085.
26. Eustace AJ, Crown J, Clynes M, O'Donovan N,. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med. 2008; 6: 53.
27. Homsi J, Cubitt CL, Zhang S, et al. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 2009; 19: 167-175.
28. Buettner R, Mesa T, Vultur A, Lee F, Jove R,. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res. 2008; 6: 1766-1774.
29. Curtin JA, Busam K, Pinkel D, Bastian BC,. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24: 4340-4346. (Pubitemid 46630793)
30. Pereira PR, Odashiro AN, Marshall JC, Correa ZM, Belfort R Jr, Burnier MN Jr,. The role of c-kit and imatinib mesylate in uveal melanoma. J Carcinog. 2005; 4: 19.
31. Smalley KS, Sondak VK, Weber JS,. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol. 2009; 24: 643-650.
32. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007; 67: 2226-2238. (Pubitemid 46424242)
33. Konecny GE, Glas R, Dering J, et al. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br J Cancer. 2009; 101: 1699-1708.
34. Sosman J, Puzanov I,. Combination targeted therapy in advanced renal cell carcinoma. Cancer 2009; 115 (10 suppl): 2368-2375.